NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
BON Natural Life Limited BON
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$18.7M
▼ 21.7% vs FY2024
EPS · FY25
$-0.72
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-3.9%
Net margin · FY25
-10.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 18.7M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 11 cents on every revenue dollar this year.
Per share
USD -0.72
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-3.9%
Return on equity, FY2025
ROE
Operating margin-8.7%
Net margin-10.7%
Return on assets-2.7%
Each USD of equity lost 4 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+0.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−14.5%
+0.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 85.2M
total assets, end of FY2025
Total assetsUSD 85.2M
EquityUSD 57.6M
CashUSD 6.3M
Gross debtUSD 1.9M
Net debtUSD -4.3M
Current ratio1.74×
The company holds more cash than debt.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.72
4.14
124.92
7.43
0.68
0.58
0.50
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−3.9
1.0
14.1
22.4
25.1
28.8
·
Shares out B
·
0.00
0.00
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed